Postmarketing analysis of aflibercept-related sterile intraocular inflammation

JAMA Ophthalmology

Volumn 133, Issue 4, 2015, Pages 421-426

  Hahn, Paul ^a   Chung, Mina M ^b   Flynn, Harry W ^c   Huang, Suber S ^d   Kim, Judy E ^e   Mahmoud, Tamer H ^a   Sadda, Srinivas R ^f   Dugel, Pravin U ^g  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e MEDICAL COLLEGE OF WISCONSIN   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g RETINAL CONSULTANTS OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CORTICOSTEROID; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; GLUCOCORTICOID; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; AGE; AGED; ANTIBIOTIC THERAPY; ARTICLE; CORTICOSTEROID THERAPY; DISEASE COURSE; DRUG SAFETY; ENDOPHTHALMITIS; EYE INFLAMMATION; FEMALE; HOSPITAL PATIENT; HUMAN; INTERMETHOD COMPARISON; INVASIVE PROCEDURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TOPICAL TREATMENT; UNITED STATES; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY; VITREOUS BIOPSY; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CHOROIDAL NEOVASCULARIZATION; EYE PAIN; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; MIDDLE AGED; RETINAL VEIN OCCLUSION; STATISTICS AND NUMERICAL DATA; TIME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; ENDOPHTHALMITIS; EYE PAIN; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; RETINAL VEIN OCCLUSION; RETROSPECTIVE STUDIES; TIME FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84928252920     PISSN: 21686165     EISSN: 21686173     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2014.5650     Document Type: Article

References (4)

1. Food and Drug Administration. Warning letter from FDA to Franck's pharmacy [on file on the FDA website]. http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/2012/ucm312645.htm. Accessed July 29, 2014.
2. Hahn P, Kim JE, Stinnett S, et al; American Society of Retina Specialists Therapeutic Surveillance Committee. Aflibercept-related sterile inflammation. Ophthalmology. 2013;120(5):1100-101.e1, 5.
3. Goldberg RA, Shah CP, Wiegand TW, Heier JS. Noninfectious inflammation after intravitreal injection of aflibercept: clinical characteristics and visual outcomes. Am J Ophthalmol. 2014;158(4):733-737.e1.
4. Glading JA, Lake SR, Craig JE, Supramaniam D. Delayed onset panuveitis following intravitreal aflibercept injection [published online June 11, 2014]. BMJ Case Rep. doi:10.1136/bcr-2013-202515.